Jarislowsky, Fraser Ltd’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$6.67M Sell
52,037
-1,410
-3% -$172K 0.04% 97
2025
Q2
$6.47M Sell
53,447
-700
-1% -$78.9K 0.04% 98
2025
Q1
$6.04M Buy
54,147
+655
+1% +$69.7K 0.04% 97
2024
Q4
$5.21M Sell
53,492
-3,275
-6% -$349K 0.03% 102
2024
Q3
$6.53M Buy
56,767
+39
+0.1% +$4.42K 0.04% 98
2024
Q2
$6.04M Sell
56,728
-4,585
-7% -$460K 0.04% 97
2024
Q1
$5.93M Sell
61,313
-2,733
-4% -$280K 0.03% 107
2023
Q4
$6.47M Sell
64,046
-2,993
-4% -$289K 0.04% 102
2023
Q3
$6.83M Sell
67,039
-5,324
-7% -$540K 0.04% 96
2023
Q2
$7.3M Sell
72,363
-8,466
-10% -$847K 0.04% 96
2023
Q1
$7.44M Sell
80,829
-4,505
-5% -$393K 0.05% 95
2022
Q4
$7.74M Sell
85,334
-8,906
-9% -$750K 0.05% 98
2022
Q3
$7.16M Sell
94,240
-12,562
-12% -$1.04M 0.05% 97
2022
Q2
$9.03M Sell
106,802
-23,803
-18% -$2.09M 0.06% 97
2022
Q1
$11.5M Sell
130,605
-86,301
-40% -$7.47M 0.06% 94
2021
Q4
$19M Sell
216,906
-57,630
-21% -$4.79M 0.09% 83
2021
Q3
$22.5M Sell
274,536
-40,386
-13% -$3.63M 0.11% 77
2021
Q2
$28.7M Sell
314,922
-124,014
-28% -$11M 0.13% 73
2021
Q1
$37.5M Buy
438,936
+6,775
+2% +$608K 0.19% 64
2020
Q4
$40.8M Sell
432,161
-21,243
-5% -$1.86M 0.21% 62
2020
Q3
$39.4M Sell
453,404
-9,687
-2% -$839K 0.23% 59
2020
Q2
$40.4M Buy
463,091
+22,443
+5% +$1.94M 0.25% 58
2020
Q1
$36.3M Buy
440,648
+1,812
+0.4% +$162K 0.26% 56
2019
Q4
$41.6M Buy
438,836
+706
+0.2% +$63.3K 0.22% 61
2019
Q3
$38.1M Buy
438,130
+5,360
+1% +$481K 0.21% 62
2019
Q2
$39.5M Sell
432,770
-44,343
-9% -$3.75M 0.24% 63
2019
Q1
$41.1M Sell
477,113
-4,598
-1% -$369K 0.26% 60
2018
Q4
$37M Sell
481,711
-3,553
-0.7% -$277K 0.25% 61
2018
Q3
$38M Buy
485,264
+1,041
+0.2% +$77K 0.24% 62
2018
Q2
$32.8M Sell
484,223
-2,174
-0.4% -$150K 0.2% 66
2018
Q1
$35.2M Buy
486,397
+33,006
+7% +$2.51M 0.22% 67
2017
Q4
$34.1M Buy
453,391
+221,817
+96% +$16.7M 0.2% 65
2017
Q3
$17.8M Buy
231,574
+30,639
+15% +$2.31M 0.11% 85
2017
Q2
$15M Buy
200,935
+16,234
+9% +$1.15M 0.1% 93
2017
Q1
$12.3M Buy
184,701
+22,425
+14% +$1.49M 0.08% 102
2016
Q4
$10.6M Buy
162,276
+11,761
+8% +$763K 0.07% 106
2016
Q3
$10.6M Buy
150,515
+70,662
+88% +$5.15M 0.07% 103
2016
Q2
$5.9M Buy
79,853
+3,495
+5% +$241K 0.04% 90
2016
Q1
$4.96M Buy
76,358
+2,094
+3% +$142K 0.03% 114
2015
Q4
$5.72M Buy
74,264
+1,722
+2% +$137K 0.04% 111
2015
Q3
$5.97M Sell
72,542
-593
-0.8% -$52.8K 0.04% 109
2015
Q2
$6.44M Buy
73,135
+949
+1% +$87.1K 0.04% 107
2015
Q1
$6.38M Buy
72,186
+4,532
+7% +$402K 0.04% 108
2014
Q4
$5.62M Buy
67,654
+669
+1% +$55.5K 0.03% 110
2014
Q3
$5.65M Sell
66,985
-1,674
-2% -$135K 0.03% 108
2014
Q2
$5.57M Sell
68,659
-111
-0.2% -$8.73K 0.03% 104
2014
Q1
$5.24M Sell
68,770
-1,674
-2% -$122K 0.03% 107
2013
Q4
$5.07M Sell
70,444
-10,267
-13% -$714K 0.03% 106
2013
Q3
$5.55M Buy
80,711
+134
+0.2% +$8.87K 0.03% 104
2013
Q2
$5.11M Buy
+80,577
New +$5.24M 0.03% 100

Other funds holding NVS

Jarislowsky, Fraser Ltd's NVS Position: Q3 2025 in Review

Jarislowsky, Fraser Ltd reduced its Novartis (NVS) stake by 2.6% in Q3 2025, selling an estimated $172K and leaving 52,037 shares worth $6.67M. The position accounts for 0.04% of the portfolio, ranked #97.

Jarislowsky, Fraser Ltd first reported a position in NVS in Q2 2013 and has held it in 50 quarters since. The position peaked at $41.6M in Q4 2019. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.

  • Jarislowsky, Fraser Ltd held 52,037 shares of Novartis worth $6.67M as of Q3 2025.
  • Jarislowsky, Fraser Ltd sold 1,410 Novartis shares in Q3 2025, an estimated $172K.
  • Novartis made up 0.04% of Jarislowsky, Fraser Ltd's portfolio in Q3 2025, its #97 holding.
  • Jarislowsky, Fraser Ltd first reported a position in Novartis in Q2 2013 and has held it in 50 quarters since.
  • Jarislowsky, Fraser Ltd's Novartis position peaked at $41.6M in Q4 2019.
  • 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.

Based on Jarislowsky, Fraser Ltd's 13F filing for Q3 2025, filed 21 Oct 2025.